|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01681 CONSUN PHARMA
Nominal 
14.130 +0.340 (+2.466%) | 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/12 RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | |
| Turnover | 1,784,688 | 13.777% | 3,417,355 | 2,967,235 | 2,590,115 | 2,339,650 |
| Cost of Sales | (332,620) | -7.582% | (750,235) | (725,133) | (668,437) | (576,738) |
| Gross Profit | 1,452,068 | 20.137% | 2,667,120 | 2,242,102 | 1,921,678 | 1,762,912 |
| 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/12 RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | (535) | -29.882% | (1,597) | (66) | 0 | 0 | |
| Profit / (Loss) before Taxation | 698,339 | 30.473% | 1,196,422 | 1,020,106 | 863,703 | 746,393 | |
| Taxation | (100,195) | 209.349% | (107,290) | (102,732) | (77,149) | (62,696) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | (2,835) | -37.692% | (11,065) | (6,916) | (2,020) | (790) | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 595,309 | 19.468% | 1,078,067 | 910,458 | 784,534 | 682,907 | |
| 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/12 RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | |
| Net Finance Costs / (Income) | (38,024) | -6.343% | (80,922) | (63,413) | (47,653) | (41,481) |
| Depreciation & Amortisation | 32,381 | 4.712% | 66,587 | 63,993 | 78,089 | 76,355 |
| Directors' Emoluments | -- | -- | -- | 23,890 | 41,942 | 39,301 |
| 2026/06 - Interim | %Chg (Compare to Interim) | 2025/12 | 2024/12 | 2023/12 | 2022/12 | |
| Auditor's Opinion Status | N/A | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2026/06 - Interim | %Chg (Compare to Interim) | 2025/12 | 2024/12 | 2023/12 | 2022/12 | |
| EPS (cts) | 71.000 | 20.339% | 127.000 | 111.000 | 99.000 | 86.000 |
| DPS (cts) | 32.879 | -- | 64.501 | 55.372 | 68.015 | 26.265 |
| Dividend Payout Ratio (%) | 46.308% | -- | 50.788% | 49.884% | 68.702% | 30.541% |
| Cash flow per share ($) | -- | -- | 1.429 | 1.324 | 1.035 | 1.199 |
| NBV per share ($) | 5.674 | -- | 5.345 | 4.824 | 4.472 | 3.897 |
| Remarks: | Real time quote last updated: 28/08/2026 18:00 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 595,309 |
| %Change | 19.468% |
| EPS / (LPS) | RMB 0.710 |
| NBV Per Share (¥) | RMB 5.674 |